ProCE Banner Activity

International Experts Address HCP Questions on BTK Inhibitors for CLL and MCL

Clinical Thought
In this commentary, expert faculty address frequently asked questions on current and emerging management strategies with BTK inhibitors for patients with CLL and MCL.

Released: November 02, 2022

Expiration: November 01, 2023

Share

Faculty

Othman Al-Sawaf

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Toby A Eyre

Toby A Eyre, MBChB, MD

Hematology Consultant
Honorary Senior Lecturer at the University of Oxford
Oxford University Hospitals NHS Trust
Oxford, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Othman Al-Sawaf, MD: honoraria: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Gilead Sciences, Janssen-Cilag, Roche; consultant/advisor/speaker: AbbVie, Janssen-Cilag, Gilead Sciences, Roche; researcher (institution): AbbVie, BeiGene, Janssen/Pharmacyclics, Roche; travel/accommodations/expenses: AbbVie, Gilead Sciences, Janssen-Cilag, Roche.

Toby A Eyre, MBChB, MD

Hematology Consultant
Honorary Senior Lecturer at the University of Oxford
Oxford University Hospitals NHS Trust
Oxford, United Kingdom

Toby Eyre, MBChB, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Incyte, Janssen, Kite/Gilead Sciences, Lilly, Loxo, Roche.